title: Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease.
abstract: OBJECTIVE
  The novel adipokines omentin, chemerin, and adipsin are associated with insulin resistance and the components of the metabolic syndrome. We assayed circulating levels of these molecules and examined their association with clinical, biochemical, and histological phenotypes in patients with nonalcoholic fatty liver disease (NAFLD).
  
  
  METHODS
  Serum levels of omentin, chemerin, and adipsin were assayed by enzyme-linked immunosorbent assay in 99 patients with biopsy-proven NAFLD and 75 control subjects. We analyzed associations between adipokines and the characteristics of patients with NAFLD using multivariable linear regression models.
  
  
  RESULTS
  Adipsin levels did not differ between patients and controls, whereas both omentin and chemerin levels were significantly higher in patients with biopsy-proven NAFLD than in controls (both p values <0.001). Serum omentin levels were significantly associated with C-reactive protein (r = 0.29, p < 0.01) and the degree of hepatocyte ballooning (r = 0.27, p < 0.01), whereas chemerin showed a modest association with liver fibrosis (r = 0.22, p = 0.04). After stepwise linear regression analysis adjusting for potential confounders, serum omentin levels retained their independent significance as a predictor of hepatocyte ballooning in patients with NAFLD (β = 1.42; t = 2.79, p < 0.01).
  
  
  CONCLUSIONS
  Our results suggest that serum omentin levels are raised in patients with NAFLD regardless of potential confounders and represent an independent predictor of hepatocyte ballooning.
authors.affiliation: Department of Gastroenterology, Marmara University School of Medicine, Altunizade, Istanbul, Turkey. yusufyilmaz@uludag.edu.tr
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yilmaz
authors.forename: Oya
authors.initials: O
authors.lastname: Yonal
authors.forename: Ramazan
authors.initials: R
authors.lastname: Kurt
authors.forename: Yesim Ozen
authors.initials: YO
authors.lastname: Alahdab
authors.forename: Fatih
authors.initials: F
authors.lastname: Eren
authors.forename: Osman
authors.initials: O
authors.lastname: Ozdogan
authors.forename: Cigdem Ataizi
authors.initials: CA
authors.lastname: Celikel
authors.forename: Nese
authors.initials: N
authors.lastname: Imeryuz
authors.forename: Cem
authors.initials: C
authors.lastname: Kalayci
authors.forename: Erol
authors.initials: E
authors.lastname: Avsar
mesh_terms: D001706:Biopsy; D016022:Case-Control Studies; D018925:Chemokines / Q000097:blood*; D011416:Complement Factor D / Q000032:analysis*; D016207:Cytokines / Q000097:blood*; D005234:Fatty Liver / Q000097:blood* / Q000473:pathology*; D005260:Female; D058851:GPI-Linked Proteins / Q000097:blood; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged
chemical_list: D018925:Chemokines; D016207:Cytokines; D058851:GPI-Linked Proteins; C432397:ITLN1 protein, human; D036341:Intercellular Signaling Peptides and Proteins; D037102:Lectins; C478630:RARRES2 protein, human; D011416:Complement Factor D